| 本文已被：浏览 919次 下载 935次 |
码上扫一扫！ |
|
|
| The evolution of prognostic and predictive markers in breast cancer |
|
Hani Katerji, Huina Zhang, David G. Hicks, Bradley M. Turner
|
|
Department of Pathology, University of Rochester Medical Center, Rochester, NY 14642, the United States
|
|
| 摘要: |
| ［Abstract］ Breast cancer is the most frequent cause of cancer death in women living in less developed regions of the world, and the second leading cause of cancer death in women living in more well-developed regions of the world. Breast cancer treatment options continue to evolve, with multiple treatment modalities now available; however, finding reliable predictive and prognostic biomarkers that will aid in selecting the appropriate treatment for breast cancer patients who would most likely respond to a specific therapy is still a major challenge, and has been the focus of many research groups throughout the past few decades. In this review, we attempt to provide an overview of the current prognostic and predictive markers in breast cancer including traditional, immunohistochemical, and genomic assays, and assess the potential clinical use of these markers. |
| 关键词: Breast cancer Prognosis Prediction Biomarkers Evolution |
| DOI：10.3969/j.issn.1674-3806.2021.12.03 |
| 分类号:R 737.9 |
| 基金项目: |
|
| 乳腺癌预后和预测标志物的演变 |
|
Hani Katerji, Huina Zhang, David G. Hicks, Bradley M. Turner
|
|
14642 美国，纽约，罗切斯特市，罗切斯特大学医学中心病理科
|
| Abstract: |
| ［摘要］ 乳腺癌是世界欠发达地区妇女最常见的癌症死因，也是世界较发达地区妇女癌症死亡的第二大原因。乳腺癌治疗方案不断发展，现有多种治疗方式可供选择。然而，寻找可靠的预测和预后的生物标志物来帮助那些最有可能对特定疗法有效的乳腺癌患者选择合适的治疗方法仍然是一项重大挑战，并且这在过去的几十年里一直是许多课题组的研究焦点。在该篇综述中，我们试图对当前乳腺癌预后和预测标志物进行回顾，包括传统的、免疫组化的和基因组的分析，并评估这些标志物的潜在临床应用。 |
| Key words: 乳腺癌 预后 预测 生物标志物 演变 |
